Living Rare
Universal Truths of Patient Attitude, Action, and Advocacy in Rare Disease
Published Nov. 10, 2026 | 2 Minute Read
In pharmaceutical marketing, rare disease strategy is frequently anchored in molecular science, specialized diagnostic codes, and niche patient populations. While medical differentiation is essential, focusing solely on biological mechanisms risks overlooking a crucial reality that rare disease patient insights reveal: Across dozens of distinct rare conditions, patients share a remarkably unified human experience.
Data from the Health Union 2026 Rare Disease In America Study (n=1,404 rare disease patients and caregivers) reveals that despite varying clinical presentations, rare patients navigate remarkably similar emotional, logistical, and social hurdles. Living Rare turns those shared truths into a practical roadmap for rare disease marketers.
About the study:
- 1,404 U.S. adults surveyed
- 60 rare conditions included
- 40% had symptoms initially dismissed by healthcare providers
Rare patients aren’t who many brands assume they are
By the time a rare disease patient reaches your brand, they have often spent more than a year searching for answers, and many have had their symptoms dismissed or misdiagnosed along the way. They come to you as experienced navigators who question medical authority, do their own research, and expect proof. Brands that recognize this history, rather than assuming a smooth clinical journey, are the ones that earn their trust.
What you’ll find in the white paper
01 · The Diagnostic Odyssey and Healthcare Friction Learn why 35% of patients waited more than a year for a diagnosis and how that history shapes the way they approach brands.
02 · The Daily Impact: Loss, Adaptation, and Stigma See where rare disease takes the biggest toll and why judgment most often comes from family and friends.
03 · Financial and Top-of-Mind Worries Understand how financial strain and access to treatment sit right behind physical health on the list of patients’ worries.
04 · The Information Seekers Find out where rare patients go to learn, what they’re searching for, and why so many are ready to talk to their doctor about changing treatment.
05 · Strategic Roadmap for Rare Disease Marketers Get four clear imperatives for turning patient friction points into meaningful brand engagement.
Built for the teams who bring rare therapies to patients
This paper is written for brand, marketing, and patient services leaders at pharmaceutical and biotech companies, along with the agency partners who support them. Whether you’re preparing for launch, refreshing a patient support program, or planning next year’s strategy, it gives you patient-backed evidence to ground your decisions.
Partner with Health Union
Health Union brings together authentic patient and caregiver experiences to help pharmaceutical brands clarify decisions and uncover strategic opportunities. If you’re ready to connect with rare disease communities in a way that feels real to them, we’d love to talk.
Source: Health Union, Rare Disease In America 2026 (n=1,404 U.S. adults living with a rare condition or caring for someone who is; fielded January 12 to April 9, 2026).
